Home / Health / Heart Drug Trial Fails, Shares Plummet 80%
Heart Drug Trial Fails, Shares Plummet 80%
10 Aug
Summary
- Experimental heart drug TNX-103 failed its late-stage study goals.
- The drug was tested for pulmonary hypertension in heart failure patients.
- Company shares dropped over 80% in premarket trading.
Tenax Therapeutics reported on Monday that its experimental treatment, TNX-103, did not achieve its main objectives in a pivotal late-stage study. The drug was being investigated for patients experiencing pulmonary hypertension, a condition often linked to heart failure with preserved ejection fraction (HFpEF).
The trial results indicated no significant improvement in the distance patients could walk compared to a placebo. Furthermore, a key secondary endpoint measuring the patients' quality of life was also not met, adding to the study's disappointment.
Following this news, Tenax Therapeutics experienced a severe market reaction. The company's stock price plummeted by more than 80% in premarket trading on the announcement. This substantial decline underscores the market's concern regarding the failed trial and its implications for the company's pipeline.
